临床肝胆病杂志2025，Vol.41Issue(12)：2512-2519,8.DOI:10.12449/JCH251212
慢性乙型肝炎合并代谢相关脂肪性肝病患者特征及危险因素分析
Features and risk factors in chronic hepatitis B patients comorbid with metabolic associated fatty liver disease
摘要
Abstract
Objective To investigate the comorbidity features of chronic hepatitis B(CHB)patients comorbid with metabolic associated fatty liver disease(MAFLD),to analyze its risk factors,and to provide a basis for clinical prevention and treatment.Methods A total of 92 patients who were diagnosed with CHB in The First Affiliated Hospital of Henan University of Chinese Medicine from January 2023 to December 2024 were enrolled and divided into CHB+MAFLD group with 52 patients and CHB group with 40 patients.Related data were collected from all patients,including general information,medical history,serum biochemical parameters,virological testing indicators,and FibroScan results.The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups;the chi-square test or the Fisher's exact test was used for comparison of categorical data between two groups;the binary Logistic regression analysis was used to investigate the risk factors for CHB comorbid with MAFLD.Results There were significant differences between the two groups in sex,body mass index(BMI),antiviral therapy,duration of antiviral medication,the preference for high-fat diet or spicy foods,and the levels of alanine aminotransferase,uric acid(UA),triglyceride(TG),high-density lipoprotein cholesterol,and controlled attenuation parameter(all P<0.05).The univariate regression analysis showed that male sex,preference for high-fat diet and spicy foods,antiviral therapy,antiviral medication for>5 years,BMI≥24 kg/m2,UA>357 µmol/L,and TG>1.70 mmol/L were associated with comorbidity with MAFLD(all P<0.05);the multivariate regression analysis showed that antiviral medication>5 years(odds ratio[OR]=9.38,95%confidence interval[CI]:2.28—38.60,P=0.002),BMI≥24 kg/m2(OR=5.60,95%CI:1.75—17.88,P=0.004),and TG>1.70 mmol/L(OR=4.08,95%CI:1.17—14.31,P=0.028)were independent risk factors for CHB patients comorbid with MAFLD.Conclusion CHB comorbid with MAFLD is the result of metabolic disorders and long-term antiviral therapy.Clinical management should be enhanced for CHB patients with long-term antiviral therapy,overweight/obesity,and hypertriglyceridemia,and targeted screening and intervention strategies should be implemented.关键词
乙型肝炎,慢性/代谢相关脂肪性肝病/慢性病共病/危险因素Key words
Hepatitis B,Chronic/Metabolic Associated Fatty Liver Disease/Multiple Chronic Conditions/Risk Factors引用本文复制引用
赵晴,张丽慧,刘素彤,尚东方,张强,赵文霞..慢性乙型肝炎合并代谢相关脂肪性肝病患者特征及危险因素分析[J].临床肝胆病杂志,2025,41(12):2512-2519,8.基金项目
国家自然科学基金青年科学基金项目(82205086) （82205086）
全国名中医传承工作室建设项目(国中医药办人教函[2022]245号) （国中医药办人教函[2022]245号）
河南省中医药科学研究专项课题(2022JDZX031,2023ZXZX1092) National Natural Science Foundation of China Youth Science Foundation Project(82205086) （2022JDZX031,2023ZXZX1092）
National Famous Traditional Chinese Medicine Inheritance Studio Construction Project(Chinese Medicine Office Human Education Letter[2022]245) （Chinese Medicine Office Human Education Letter[2022]245）
Special Subject of Scientific Research on Traditional Chinese Medicine in Henan Province(2022JDZX031,2023ZXZX1092) （2022JDZX031,2023ZXZX1092）
